Departments of *Obstetrics and Gynecology, and †Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Int J Gynecol Cancer. 2014 Jan;24(1):141-8. doi: 10.1097/IGC.0000000000000028.
This study aimed to evaluate the effectiveness and feasibility of reirradiation using high-dose-rate interstitial brachytherapy (HDR-ISBT) in patients with recurrent cervical cancer.
The records of 52 consecutive women with central pelvic recurrence who were salvaged with HDR-ISBT-based reirradiation were retrospectively reviewed. Data regarding the primary disease, follow-up findings, recurrence, the treatment outcome, and toxicities were collected. Multivariate analysis was performed using the Cox proportional hazards regression model to identify predictors of the response to HDR-ISBT. Survival rate was calculated using the Kaplan-Meier method and compared using the log-rank test.
A total of 52 patients who had been treated with HDR-ISBT-based reirradiation were included in our database. The local control rate was 76.9% (40/52), and the median postrecurrence survival period was 32 months. Grade 3 or 4 late toxicities were observed in 13 patients (25%). Multivariate analysis revealed that tumor size and the treatment-free interval were significant poor prognostic factors of postrecurrence survival. In a comparison between the patients who were salvaged with HDR-ISBT-based reirradiation (ISBT group) and those who were treated with palliative therapy alone (palliative group), we found that among the patients who displayed 0 or 1 poor prognostic factors, the patients in the ISBT group survived significantly longer than those in the palliative group. In contrast, similar survival rates were seen in both groups among the patients with 2 or more poor prognostic factors.
Reirradiation using HDR-ISBT is effective and feasible in patients with recurrent cervical cancer. Our 2-clinical variable prognostic model might enable physicians to identify patients who would not derive clinical benefit from HDR-ISBT and offer them the opportunity to receive other types of treatment.
本研究旨在评估高剂量率间质近距离放疗(HDR-ISBT)在复发性宫颈癌患者中的有效性和可行性。
回顾性分析 52 例采用 HDR-ISBT 挽救性再放疗的中央盆腔复发宫颈癌患者的临床资料。收集患者的主要疾病、随访结果、复发、治疗效果和毒性等数据。采用 Cox 比例风险回归模型进行多因素分析,以确定 HDR-ISBT 反应的预测因素。采用 Kaplan-Meier 法计算生存率,并采用对数秩检验进行比较。
共纳入 52 例接受 HDR-ISBT 挽救性再放疗的患者。局部控制率为 76.9%(40/52),中位复发后生存时间为 32 个月。13 例(25%)患者出现 3 或 4 级迟发性毒性。多因素分析显示肿瘤大小和无治疗间隔时间是复发后生存的不良预后因素。在接受 HDR-ISBT 挽救性再放疗(ISBT 组)和单纯姑息治疗(姑息组)的患者之间进行比较时,我们发现在仅存在 0 或 1 个不良预后因素的患者中,ISBT 组的患者生存时间明显长于姑息组。而在存在 2 个或更多不良预后因素的患者中,两组的生存曲线相似。
复发性宫颈癌患者采用 HDR-ISBT 再放疗是有效且可行的。我们的 2 个临床变量预后模型可以帮助医生识别那些从 HDR-ISBT 中无法获得临床获益的患者,并为他们提供接受其他类型治疗的机会。